Rivaroxaban for the treatment of consumptive coagulopathy associated with a vascular malformation

J Thromb Thrombolysis. 2014 Jul;38(1):121-3. doi: 10.1007/s11239-013-1024-7.

Abstract

The localized activation of coagulation in vascular malformations can lead to a consumptive coagulopathy characterized by elevated D-dimers and a consumption of fibrinogen and platelets, eventually giving rise to a bleeding tendency. By reducing coagulation activation, anticoagulant treatment with heparin is able to limit this haemostatic dysregulation and the associated bleeding diathesis. Here, we present a case of a consumptive coagulopathy due to a large venous malformation with a sustained correction of the fibrinogen depletion and associated bleeding tendency both with subcutaneous enoxaparin and with the oral factor Xa inhibitor rivaroxaban.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Adult
  • Disseminated Intravascular Coagulation / blood
  • Disseminated Intravascular Coagulation / complications
  • Disseminated Intravascular Coagulation / drug therapy*
  • Factor Xa Inhibitors / administration & dosage*
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Humans
  • Male
  • Morpholines / administration & dosage*
  • Rivaroxaban
  • Thiophenes / administration & dosage*
  • Vascular Malformations / blood
  • Vascular Malformations / complications
  • Vascular Malformations / drug therapy*

Substances

  • Factor Xa Inhibitors
  • Fibrin Fibrinogen Degradation Products
  • Morpholines
  • Thiophenes
  • fibrin fragment D
  • Rivaroxaban